Influenza Vaccine Effectiveness against Hospitalization, Season 2021/22: A Test-Negative Design Study in Barcelona

Abstract

Effectiveness; Hospitalization; Influenza

Efectivitat; Hospitalització; Grip

Efectividad; Hospitalización; Gripe

Background: Vaccination is considered the most effective measure for preventing influenza and its complications. The influenza vaccine effectiveness (IVE) varies annually due to the evolution of influenza viruses and the update of vaccine composition. Assessing the IVE is crucial to facilitate decision making in public health policies. Aim: to estimate the IVE against hospitalization and its determinants in the 2021/22 season in a Spanish tertiary hospital. Methods: We conducted a prospective observational test-negative design study within the Development of Robust and Innovative Vaccine Effectiveness (DRIVE) project. Hospitalized patients with severe acute respiratory infection (SARI) and an available influenza reverse transcription polymerase chain reaction (RT-PCR) were selected and classified as cases (positive influenza RT-PCR) or controls (negative influenza RT-PCR). Vaccine information was obtained from electronic clinical records shared by public healthcare providers. Information about potential confounders was obtained from hospital clinical registries. The IVE was calculated by subtracting the ratio of the odds of vaccination in cases and controls from one, as a percentage (IVE = (1 − odds ratio (OR)) × 100). Multivariate IVE estimates were calculated using logistic regression. Results: In total, 260 severe acute respiratory infections (SARI) were identified, of which 34 were positive for influenza, and all were subtype A(H3N2). Fifty-three percent were vaccinated. Adjusted IVE against hospitalization was 26.4% (95% CI −69% to 112%). IVE determinants could not be explored due to sample size limitations. Conclusion: Our data revealed non-significant moderate vaccine effectiveness against hospitalization for the 2021/2022 season.

This study has been funded by the DRIVE IMI project. The DRIVE project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No. 777363); this Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the EFPIA.